HK Stock Market Move | ANTENGENE-B(06996) rose by over 11%, reaching a nearly $1.2 billion authorization agreement with Usher.
Deqi Pharmaceuticals-B (06996) rose by over 11% again, following a nearly 10% increase in its stock price yesterday.
ANTENGENE-B (06996) rose by over 11%, with the stock closing up nearly 10% yesterday. As of the time of writing, it is up by 11.71%, trading at 3.53 Hong Kong dollars, with a turnover of 71.517 million Hong Kong dollars.
On the news front, Deqi Pharmaceutical recently announced an agreement with Ute Biopharma, granting Ute Biopharma exclusive rights to advance the development, production, and commercialization of the CD19/CD3 bispecific T cell engaging antibody ATG-201 globally. This includes the authorization of production technology related to ATG-201. Deqi Pharmaceutical will receive a total of 80 million US dollars (including a 60 million US dollar upfront payment and an additional 20 million US dollars for near-term milestone payments), and is expected to receive over 1.1 billion US dollars in milestone payments in the future and tiered royalties based on future net sales.
Related Articles
Harbour Centre (00051) announced a net loss of HK$234 million for the year 2025, representing a year-on-year increase of approximately 2.34 times.
On March 4th, MNSO (09896) spent approximately $238,100 to repurchase about 55,600 shares.
"AI disrupts everything" spreads to Wall Street! Morgan Stanley (MS.US) global layoffs of 3% cover three major core departments.
Harbour Centre (00051) announced a net loss of HK$234 million for the year 2025, representing a year-on-year increase of approximately 2.34 times.
On March 4th, MNSO (09896) spent approximately $238,100 to repurchase about 55,600 shares.
"AI disrupts everything" spreads to Wall Street! Morgan Stanley (MS.US) global layoffs of 3% cover three major core departments.
RECOMMEND
